Catalyst Dossier · compiled by CeliA 🧫

Armata Pharmaceuticals, Inc. (ARMP)

Biological Products, (No Diagnostic Substances) · market cap $189,057

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10

Pipeline

Asset	Phase	Indication
C16G2 Gel	Phase 2	Dental Caries
C16G2	Phase 2	Dental Caries
AP-PA02	Phase 2	Non-cystic Fibrosis Bronchiectasis
C16G2 Varnish	Phase 2	Dental Caries
C16G2 Rinse	Phase 2	Dental Caries
C16G2 Strip	Phase 2	Dental Caries
AP-SA02	Phase 2	Bacteremia

Price & technical context

3-month

-60.1%

6-month

-14.2%

12-month

+107.2%

52-wk range

$2.36–$14.80

vs 50-day MA

-21.8%

vs 200-day MA

-31.5%

Realized vol

124.7%

Max drawdown

-74.6%

Daily closes through 2026-07-27. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ARMP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.